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Critical components of successful evaluation of clinical outcome assessments (COAs)
in multisite clinical trials and clinical practice are standardized training, administration,
and documented reliability of scoring. Experiences of evaluators, alongside patient
differences from regional standards of care, may contribute to heterogeneity in clinical
center’s expertise. Achieving low variability and high reliability of COA is fundamental
to clinical research and to give confidence in our ability to draw rational, interpretable
conclusions from the data collected. The objective of this manuscript is to provide
a framework to guide the learning process for COAs for use in clinics and clinical
trials to maximize reliability and validity of COAs in neuromuscular disease (NMD). This
is a consensus-based guideline with contributions from fourteen leading experts in
clinical outcomes and the field of clinical outcome training in NMD. This framework
should guide reliable and valid assessments in NMD specialty clinics and clinical trials.
This consensus aims to expedite study start up with a progressive training pathway
ranging from research naïve to highly experienced clinical evaluators. This document
includes recommendations for education guidelines and roles and responsibilities of key
stakeholders in COA assessment and implementation to ensure quality and consistency
of outcome administration across different settings.
Keywords: clinical outcomes assessment, clinical evaluation education, neuromuscular disease (NMD), evaluator
training, clinical trial readiness

1

November 2021 | Volume 12 | Article 735936

Duong et al.

Clinical Outcome Assessment Guidelines

INTRODUCTION
Neuromuscular disorders (NMDs) are inherited or acquired
conditions resulting in progressive muscle weakness, fatigue and
loss in function. Disease onset varies from being present at
birth to emerging in adulthood with a wide range of maximal
function achieved and variability in trajectory of progression.
Clinical outcome assessments (COAs) are used to document the
natural history of the disease, evaluate the effectiveness of various
therapies, support the registration of investigational drugs, and
monitor the impact of therapies over time. It is therefore crucial
that COAs are administered and scored in a reliable and valid
manner to provide insight on the impact of NMD processes and
progression by tracking clinical changes that may play a role in
clinical decision making and trial design (Figure 1).
Methodologic variables that have possibly contributed to
failed trials include lack of, rushed, or poorly designed clinical
evaluator training and competency (Kobak et al., 2004).
Variables that contribute to accurate COA administration go
beyond clinical experience, including conceptual understanding
of the scale and disease, didactic training on the study
protocol/objectives, ability to interact and motivate patients
across the lifespan, applied learning, and frequency of education
to reduce post-training evaluator drift. Drift is defined as
decreased consistency of rater functioning over time (Congdon,
2000; Wolfe et al., 2001; Mulsant et al., 2002; Kobak et al.,
2004, 2006; Jeglic et al., 2007). Drift occurs for many reasons
such as lack of familiarity with the scale or scoring, inadequate
training, decreased attention/fatigue, personal interpretation of
the scoring system, and loss of content knowledge for decision
making over time (Congdon, 2000; Wolfe et al., 2001).
Validity and interpretation of clinical findings can be
significantly compromised with poor reliability of COAs.
Establishing both intra-rater and inter-rater reliability is essential
to ensure that any changes in a patient’s performance are due to
the disease progression rather than evaluator error. Therefore,
to ensure assessments are valid and reliable within site clinical
evaluators (CE) for clarity multi-site trials or within repeated
clinical visits for the same person, we propose a guideline for
optimal data collection through standardized training.
Despite the importance of training CEs to perform COAs,
there are few published standards to guide the selection and
preparation of CEs to administer COAs in clinical trials
(Mulsant et al., 2002). This leads to ambiguity in training
methodology that may have a significant impact on the success
or failure of trials due to variability and inconsistency in

FIGURE 1 | Purpose of high quality Clinical outcome assessment (COA).

data collection (Kobak et al., 2004; Targum, 2006). In 1978, the
Muscular Dystrophy Association (MDA) supported the very
first studies documenting the natural history of Duchenne
muscular dystrophy (DMD) (Brooke et al., 1981). There were
key learnings for the crucial need to appropriately educate CEs
in the reliable and valid administration of COAs. First, there
needs to be established, validated and reliable outcome measures
that have the power to prove a positive or negative effect in
the disease (Brooke et al., 1983). Second, to ensure reliable
administration, significant investment of time and money is
essential for ongoing and regular quality training, even for those
experienced clinical evaluators.
Many NMDs are progressive in nature, requiring trials to be
performed longitudinally. For longitudinal, multi-site studies a
comprehensive training program including didactic and applied
education improves reliability of COAs (Gibbon et al., 1981;
Kobak et al., 2004; Targum, 2006; Walker et al., 2014). Studies
that limited training to one occasion, at an initial investigator
meeting, resulted in poor reliability in administration of COAs
(Demitrack et al., 1998).
International studies pose unique challenges with diverse
cultural and language needs, as well as varied educational
and experiential backgrounds that may impact accurate
administration of COAs (Jeglic et al., 2007). Although
documented inter- and intra-rater reliability could increase
confidence in the robustness of data, only a few studies have used
methods to document competencies in performance of COAs
such as reliability testing and/or procedural knowledge through
quizzes or skills demonstration (Personius et al., 1994; Escolar
et al., 2001; Targum, 2006; Mayhew et al., 2007; Walker et al.,
2014; Glanzman et al., 2018; Krosschell et al., 2018).
In this article, we describe two essential training components:
1. Didactic training to ensure a strong foundation of knowledge
of the disease process and COA procedures, 2. Applied or

Abbreviations: CE, clinical evaluator; ClinRo, clinician-reported outcome
measure; COA clinical outcome assessment; CRF, case report form; DMD,
Duchenne muscular dystrophy; EK, Egen classification; FDA, food and drug
administration; EMA, European Medicines Agency; GCP, good clinical practice;
GDP, good documentation practice; HHM, hand held myometry; IM, investigators
meeting; MDC, minimal detectable change; MMT, manual muscle testing;
MP, master physiotherapist; NMD, neuromuscular disorder; NSAA, north star
ambulatory assessment; ObsRO, observer-reported outcome measure; PerfRO,
performance outcome measure; PRO, patient reported outcome measure; QC,
quality control; QMT, quantitative muscle testing; ROM, range of motion; SOP,
standard operating procedure; 6MWT, 6-min walk test; PFT, pulmonary function
testing.
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practice-based training (Kobak et al., 2004, 2005; Targum, 2006;
Jeglic et al., 2007; Steeves et al., 2007). One reason for the lack
of adoption of universal education and training guidelines could
be that the process of training CEs can be costly and timeconsuming; and if not initiated early enough may lead to study
start-up delays.
This guide aims to provide a framework for an education and
skill acquisition training plan for the administration of COAs.
The plan may be used both within and across sites to assess
the impact the NMD has on an individual’s strength, function,
and participation in daily activities. The primary objective is to
describe a common framework for improving standardization
and accuracy in the education and administration of COAs
in NMD. These recommendations are intended to provide a
construct for clinicians, investigators, industry, pharmaceutical
companies, and clinical research organizations to develop their
own education and training plan that encompass key components
required for quality administration of COAs. We hope these
guidelines developed by a group of leading expert trainers in
NMD with a wide breadth of experience from early natural
history studies to international multi-site clinical trials will
provide a pathway to improve COA implementation across
different types of studies and programs involving NMD. This
framework will promote efficient, reliable, valid administration
and scoring of COAs administered by CEs.

TABLE 1 | Clinical outcome assessment (COA) physical therapists experience.
COA
Expert

Research Training
Experience (years)

Neuromuscular
Experience
(years)

1

19

15

17

2

42

22

15

3

18

10

17

4

25

8

14

5

40

35

20

6

13

7

11

7

34

10

15

8

43

39

39

9

43

43

43

10

39

15

30

11

20

11

18

12

30

16

16

13

21

11

16

14

21

10

18

TOTAL

408

252

289

Min

13

7

11

Max

43

43

43

29.1

18.0

20.6

Average

experience with the NMD patient population and have had
prior training on the COAs. These groups require different
teaching and training approaches. It is important to ensure
novice and proficient learners start their training with a
similar foundation of knowledge whilst still recognizing and
acknowledging a CEs experience. With increased clinical and
research experience, novice learners may eventually become
proficient learners requiring different approaches to move
beyond basic administration of the COA to active learning
and critical thinking indicating integration of basic knowledge,
understanding and interpretation of the content based on the
patient population (Noonan et al., 2012). This is important for
clinical trials that may have an impact on the historical phenotype
of the population requiring the CE to analyze movement patterns
and score the COA in a standard manner with a phenotype
that may have not been previously taught or described. The
level of training that will be required of a CE will depend on
whether the COAs will be implemented in a clinic setting or in
a clinical trial.

MATERIALS AND METHODS
An international group of 14 physical therapist (PT)
clinical researchers with expertise in NMD disease and
COAs attended a 1 day in-person meeting in Warrenton,
VA, United States on December 04, 2015, to develop
guidelines in COA administration in Duchenne Muscular
Dystrophy (Supplementary Material). Since that time,
there has been a dramatic increase in clinical trials for
rare NMDs and we decided to have 3 subsequent virtual
meetings to evaluate current practices and propose guidelines
from experience and lessons learned for CE qualifications
and trainings from these studies. Proposed guidelines
included minimum training criteria and recommendations
for implementation.
The contributing clinical experts have on average 29.1 years of
clinical experience and 18.0 years of training of COAs in NMD
(Table 1). These PTs have been leaders in establishing the current
standards and recommendations used in multi-site studies and
clinical trials for drug approvals through the Food and Drug
Administration (FDA) and European Medicines Agency (EMA)
over the last 40 years.

Training Process
This consensus guideline provides practical suggestions to ensure
objective and accurate administration of COAs. Key stakeholders
should be identified prior to study initiation to develop a training
plan which should include:

Recommendations for Clinical Outcome
Assessment Education
Because experience levels among CEs can be diverse, we
have provided guidelines for both novice and proficient
evaluators (Figure 2). We deem a novice evaluator to have
minimal clinical experience and/or, research experience and/or
proficiency administering the COAs. Proficient evaluators have

Frontiers in Genetics | www.frontiersin.org
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Experience
(years)

X Qualification requirements of CEs.
X Contents of training.
X Testing methods and monitoring to ensure competency of
accurate COA administration and scoring across a trial to
minimize drift.
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FIGURE 2 | Levels of COA experience and knowledge.

Studies show that clinical experience is only one variable in
accuracy and improved scoring of COAs. The most significant
factor in improved accuracy in scoring COAs is CE foundational
knowledge, familiarity with patients in NMD and frequency of
training sessions. Targum (2006) found that with at least one
training session, CEs of all clinical experience levels improved,
but those who participated in 5 or more training sessions
performed significantly better than those who attended only 1
session. Multiple training sessions should continuously build on
the CEs current skill level, utilizing different modes of teaching.
Training should consist of 2 parts: 1. Didactic learning 2. Applied
learning (Table 2). For performance based COAs where quality
of movement is scored, this education model increases familiarity
with scoring the COAs and accuracy in performance. Cusick et al.
(2005) found that training was associated with higher perceived
level of performance and familiarity with the test items, improved
reliability, decreased error, and improved internal consistency
of test administration. Training reduced personal interpretation
and allowed for understanding of applied theoretical constructs
of each item which improved and standardized method of
test item scoring.
Most studies focus on didactic learning, typically provided at
only one investigators’ meeting. This provides understanding of
the protocol, objective of the COA and a general overview of the
known natural history of the disease. Cusick et al. (2005) found
that this was insufficient for retention of knowledge and accuracy
of administration of COAs. As didactic learning only provides
conceptual knowledge on scale development, further in-depth
instruction should cover essential components of the assessment
and highlight common mistakes in administration and scoring.
Applied learning typically has a more hands-on approach that
may be done in person through different methods (Table 2)
that improve the CEs critical thinking skills and translation
of information. This can ensure the CE is adhering to the
standard administration from the COA manual, critically think
through patient scenarios, and clarify vague or contradictory
information as needed. Several studies have applied this type of
learning through hands-on training, video review and reliability

The training plan should include educational material that
addresses different types of learners. Additionally, the training
plan should also include an escalation plan to upskill CEs who
do not meet professional and experiential criteria of training at
the time of study start up, as this may impact the data collection.
The training plan should also address a strategy regarding
CEs who have been trained and do not evaluate a patient.
An example would be a novice CE who has been trained for
3 months and has not assessed a patient within the clinical trial.
This affects information retention and increases the risk of drift
and associated variability in COA administration. Methods to
mitigate this may include a re-training plan for those CEs in the
instance of delayed study start up or patient recruitment at sites.

Training Methods
Basic training of COAs should not only include information
about scale administration and item-by-item scoring, but
also include training in NMD topics of disease mechanisms,
pathophysiology and expected disease progression. Additional
topics include:
Good clinical practice (GCP).
Good documentation practice (GDP).
Knowledge of clinical research practice and study design.
Internal validity risks and best management practices.
Roles and responsibilities as a research/clinical evaluator
and as key stakeholders in COA administration.
X Standardized training plan in core COAs used in each
subset of NMD.

X
X
X
X
X

Advanced training to reach a proficient level should build
upon the basic training concepts with increased applied
learning skills to cement critical thinking skills required
for assessing challenging or complex patients (Figure 2).
Through applied situational learning, regular delivery of COAs,
and exposure to patients with NMD, proficient, and expert
learners should recognize similar characteristics/patterns across
COA administration/scoring and NMD to increase fluid
tacit knowledge.
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TABLE 2 | Examples of didactic and applied education.
Didactic education

Applied education

Conceptual knowledge: Scale development, Scale construct, COA overview,
Reliability: May be performed with video review or in person.
Review of manual of operations from item-by-item basis highlighting key points Hands on lab to improve test administration and handling techniques ie: dolls, patients
Discussion of scoring construct

Practice in-person with volunteers with NMD, or using simulation

Review of video to demonstrate items or live demonstration

Video Review and discussion on scoring: Polling, Quizzes to facilitate discussion

Training in the study specific NMD

Quality control video review and feedback to enhance test administration throughout
study.

(Personius et al., 1994; Escolar et al., 2001; Ditunno et al., 2005;
Mayhew et al., 2007; Steeves et al., 2007; Glanzman et al., 2018;
Krosschell et al., 2018).

later be collated to support treatment efficacy comparing trial
data to the natural disease progression. The novice level training
will provide a strong foundation for the CE to acquire experience.

Qualification Requirements of Clinical Evaluator

Establishing Initial Reliability

Factors to consider regarding CE qualification during site
selection include pre-determined minimal educational
requirements, clinical experience and training required to
perform and score COAs accurately. Since many COAs
measuring treatment efficacy are function and performancebased assessments, PTs are a logical choice to serve as CEs. Since
they receive extensive training in functional anatomy, physiology,
and biomechanics as well as the psychometric properties of
testing. They develop astute observational and palpation skills,
which are necessary for assessments of strength and function.
In addition, PTs have the skills to analyze movement and ensure
that the quality of movement is aligned with the test objective.
Similarly, PTs are skilled in motivating patients to perform
movements and activities that may be challenging but required
for a valid assessment, and can support with hands-on skills
crucial to positioning for testing. Although most evaluations are
currently performed by a licensed PT, these guidelines can also
be used to instruct other healthcare professionals with similar
backgrounds and sufficient documented experience. However,
it is important to note that training and applied practice will
require additional time and effort if a healthcare provider does
not have the necessary foundational knowledge. Planning and
providing for ample time for both didactic and applied practice
opportunities is key to cementing knowledge and achieving valid
and reliable COA administration and scoring.
A centralized process for training in multi-site clinical trials
is essential for consistency in standardizing COA administration
and data collection. With global diversity in CE experience
and knowledge of COAs, centralization of the training process
ensures consistency in who may perform COAs, current level
of education, experience, acquisition, and maintenance of skills
throughout the duration of the study (Kobak et al., 2004).

Evidence of an acceptable level of COA reliability should be
achieved by the CE following didactic training, but prior to
conducting any study assessments. Reliability should (1) Be
established between the COA experts (considered the gold
standard training evaluator), (2) Involve all study CEs responsible
for COA administration, (3) Follow a reliability plan with preestablished objective minimal criteria. The criteria should be
based on the standard error of measurement for each assessment
if available. Ideally, reliability testing should consider inter-rater
reliability which tests the CE’s ability to administer and score
the test consistently and can be done through video evidence
or by assessing a live patient (Glanzman et al., 2018). In-person
reliability is essential but requires understanding of fatigue and
motivational variables that may impact COA performance.
Studies have also successfully used video reliability as
part of annual and refresher trainings in clinical trials in
NMD (Glanzman et al., 2018; Krosschell et al., 2018). It is
important, however, to ensure videos are of sufficient quality
with appropriate camera angles to promote accurate scoring.
For studies and clinical trials, intra-rater reliability may also
be established utilizing the study design. These visits may be
integrated into a screening and baseline visit to compare intrarater reliability.
To demonstrate and document knowledge acquisition, CEs
typically must pass a written or verbal quiz of the material. For
administration competency, the CEs should be evaluated on a
pre-determined level of scoring agreement with the COA expert.
In addition, it is highly recommended that inter-rater reliability
between CEs working in the same institution is assessed to ensure
consistency. Programs should consider having opportunities and
time built into budgets and schedules to ensure CEs have the
resources needed to monitor and maintain reliability within
their own site through periodic simultaneous evaluation of the
same patient(s).

Training for Novice Clinical Evaluators
Training at the novice level should introduce the theory
and development strategy behind disease-specific standardized
COAs. Didactic aspects of the training could include video review
in addition to the essential components of administering and
scoring assessment (Table 3). This might be accomplished as
part of an investigator meeting. The routine use of standardized
COAs in the clinic provides objective monitoring of patients and
improves clinical decision-making (Figure 1). Clinical data must
be of the same high quality and rigor as in clinical trials as it may
Frontiers in Genetics | www.frontiersin.org

Testing Methods and Long-Term Monitoring of
Clinical Outcome Assessment for Quality Assurance
Frequency of training throughout the study for knowledge
acquisition and skill retention should be pre-determined as part
of the training plan. After training, monitoring for quality control
of COAs, calibration and CE drift is important (Kobak et al.,
2004; Samuels et al., 2019). Different approaches have been used
for re-training in clinical trials including annual and quarterly
5
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TABLE 3 | Training plan overview.
Foundational knowledge education plan
Trainer

COA Expert Physical Therapist Trainer

Trainee

Qualified Physical Therapist or comparable professional

Prerequisites

Preferred NMD specialty clinic experience
COA experience for clinic or trials

Training Objective

Entry level knowledge on disease process, implementing and interpreting COAs and research best practice

Core Content

• Didactics of NMD disease pathophysiology
• Biomechanics of movement
• Applied: Hands-on lab and video review of COAs and functional scoring scale, Reliability with video

medical and allied health professions. It is important to take this
into consideration when determining the training requirements
and quality assurance for COAs.

trainings where the focus is to highlight common errors seen
in the quality control data or video review. Confirmation trials
have also used video review and feedback throughout the trial
to provide immediate advice through a “buddy” system that
promotes ongoing learning and consistency throughout a trial.
This approach facilitates open communication and a supportive
relationship between the COA expert trainer and the CE to
enhance the learning process.
Retraining should focus on knowledge retention and building,
not a repeat of the original didactic information. Considering
the fact that many NMDs are considered rare or ultra-rare,
there should be a focus on learning over time as expertise will
develop with repeated CE exposure to patients with these specific
conditions. This may be done through traditional video review
and discussion of participants from the study, particularly if there
is a change in phenotype. Other studies have utilized technology
for enriched trainings utilizing interactive web portals to enhance
knowledge acquisition (Samuels et al., 2019). A multi-site study
for a depression trial that utilized traditional and web-based
tutorials showed improvements in didactic and applied skills
that enhanced accessibility, training and cost effectiveness (Kobak
et al., 2006). Consideration regarding CE burden and different
modes of training should be taken into account, including hybrid
models of web-based, videoconference and in-person trainings.
The ongoing, periodic retraining is relevant for longer-term
studies to ensure accuracy in COA administration and reliability.

DISCUSSION
With the current landscape of NMD it is critical to standardize
study training to ensure robust data in clinical trials and
accurate long-term monitoring in clinic, post marketing, and
natural history studies. Currently in studies involving NMD,
COA training varies across different disease cohorts but
it usually consists of a combination of didactic teaching
of COAs and disease presentations, video review of COA
administration followed by discussion, demonstration and
practice of performing the COAs. These usually occur at
investigator meetings or on-site training visits. Intra-rater
reliability may be established in some protocols as part of
the study design and inter-rater reliability may be established
via video review or in person patient testing (Brooke et al.,
1981; Florence et al., 1984; Personius et al., 1994; Escolar
et al., 2001; Mayhew et al., 2007; Krosschell et al., 2011, 2018;
Glanzman et al., 2018).
This guideline utilizes the extensive experience from
global expert physical therapist/clinical evaluator trainers to
provide recommendations for training and education in COA
administration. Quality COAs impact the interpretability of
data that is used as efficacy endpoints in NMD trials and guides
clinical decision-making and planning treatment options. As
part of a Clinical Globalization of DMD Outcomes project, we
developed a DMD training guideline and standard operating
procedures (Supplementary Material).
The accuracy of COA administration relies on many
variables including existing knowledge, experience and type
of training completed. Targum (2006) found that clinical
experience was not statistically impactful in the accuracy
of COA scoring in neurology trials but identified that the
number of training sessions was the more significant factor.
All CEs need comprehensive and ongoing training regardless
of clinical experience. Frequent training throughout a study
improves familiarity with COAs but is particularly important in
trials that have significant impact in changing the pre-treated
phenotype. CEs must acquire skills to accurately and reliably
administer COAs with different types of patients within the
construct of test.

Considerations for International Multi-Site Studies
Factors such as linguistics, behavior and cultural differences
may impact COA administration, knowledge acquisition, and
interpretation for global trials. Consistency with training is key
to ensure accuracy and standardization. We recommend that
the same manuals, study worksheets and training materials
be translated into the site’s native language and presented to
all sites within the study. The material must be translated
and back translated in consultation with a COA expert to
make necessary adjustments based on clinical interpretational
linguistic differences. To ensure accuracy of translation and
understanding of COAs, we also recommend real time, or
simultaneous translation for both the didactic and applied
education series. From our experience, errors in translation
have been clarified during in-person trainings that included
simultaneous translation for international studies. It is important
to consider educational requirements and scope of professional
practice as they can vary significantly among international
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• Engagement by using technology allows for knowledge
transfer, uptake and retention.
• Intra-rater reliability is often higher than inter-rater
suggesting the same CE per patient throughout the trial
especially at key study milestones is important to consider.
• Pre-Study site selection should include CE training
experience so this may be integrated into a study training
plan to provide sufficient timelines for CE training,
preventing delays in study start up and recruitment.

Clinical care and monitoring have improved with
clinical trial experience and training particularly at sites
who lacked standardized methods for COA administration.
Early harmonization of manuals and standard operating
procedures in outcomes from DMD trials have provided
unique opportunities to combine and analyze data from various
sources. The Collaborative Trajectory Analysis Project (CTAP)
leverages natural history, placebo and real-world clinical data to
understand the heterogeneity in disease progression and identify
prognostic factors to loss of key clinical milestones (Mercuri
et al., 2016; Goemans et al., 2020). Efforts, such as these in COA
administration, are essential for rare and ultra-rare NMD as they
allow for data modeling that may impact clinical trial design,
characterize disease trajectories, assess meaningful change, and
be used for external controls and interpretation of outcomes.
There is increased cost associated with comprehensive,
standardized and effective training. This may be a reason for the
lack of adoption of universal education and training guidelines of
COA. However there is a much higher financial and emotional
cost of a failed trial. Comprehensive training reduces variability
in COAs which may impact study design in estimation of
expected effect size and power. Several studies have found that
the training method of COAs may have potential impact on
failed trials in behavioral sciences and Central Nervous System
Disorders (Mulsant et al., 2002; Kobak et al., 2004; Jeglic et al.,
2007). With enormous costs of large multi-site international
trials in rare disease, it is imperative to appropriately document
methodological approaches to improving accuracy and reliability
of COAs in clinical trials and in post marketing studies. Cusick
et al. (2005) assessed “trained” and “untrained” CEs for the
evaluation of upper limb function and found that even if provided
with a manual for the study, none of the CEs read the manual, and
only the trained group reviewed the details of the manual during
the training. In a fluoxetine study, lack of inter-rater reliability
and training contributed to large variability in depression scale
scores and such was hypothesized as a major factor in the failed
trial (Mulsant et al., 2002).
Since the initial MDA multi-site DMD training study (Brooke
et al., 1981), aspects of the training model described in this
guideline have been administered across different NMD studies
from natural history to large multi-site international gene therapy
trials with good success. We have built on these previous
experiences to refine variables that result in improved accuracy,
quality and delivery of COA training.

One of the limitations of this guideline is that we do not
have empirical data to support recommendations as results of
training and reliability across programs is often proprietary and
not reported. This consensus is based on the collective experience
of global COA expert trainers in the NMD field. However, one
of the strengths of this guideline is the wealth of experience of
the authors from design of original natural history studies for
Duchenne Muscular Dystrophy over 40 years ago to the current
gene therapy trials where we gained vast amounts of experience
in a very different pre vs. post treatment phenotype. These
learnings are important as the NMD trial landscape shifts from
using disease specific COAs designed based on pre-treatment
compensations and now moving to a treatment era that will
include combination therapies resulting in changes in function
and disease progression. We acknowledge that the authors are
trainers and advisors on many large NMD clinical trials and
may be viewed as possible conflicts of interest. However, our
experiences and recommendations align with published studies
in behavioral and neurological research on the importance and
need for centralized, standardized training to ensure reliable
administration and scoring of COAs (Kobak et al., 2004; Targum,
2006; Jeglic et al., 2007; Walker et al., 2014). We have collated
our experiences to provide a practical approach toward this
goal and the contents of this guide may be used in context
of the specific NMD, purpose and phase of the trial. Many
trials have primary and secondary efficacy endpoints based on
COAs performed by CEs therefore training methods must be
thoughtfully and rigorously employed to ensure longstanding
high data quality across diverse clinical and research settings.
We hope that the collective lessons learned summarized in this
consensus-based guideline will result in quality and consistency
in COA administration allowing for improved confidence in data
interpretation to further advance the clinical understanding of
the changing landscape in neuromuscular disorders.

• Training plan must be pre-determined to include
qualifications of CE, COA training content materials,
and training approach and methods including re-training
for longitudinal studies.
• Manuals for the validated COA should be harmonized
across the study and consistent with published material.
• Previous CE experience and training with COAs should
be documented to decrease redundancy in training across
disease groups and adapt education material to meet
individual learning styles and needs.
• Timely and regular feedback is essential to optimize
learning and improvement of COA quality.
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Advanced Learner
Individual with experience and comfort administering and
scoring common COA; selects appropriate COA for diagnosis;
assesses challenging and complex patients and cohorts.

Clinical Evaluator
Individual, often a physical therapist, who will perform clinical
research assessment of outcomes that will be implemented in
clinical trials or in the clinic. This individual will have training
in implementation of clinical research assessment of outcomes in
a standardized manner following good clinical practice.
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shifting confirmatory clinical research studies (phase 3) into the
post-marketing arena. Post marketing study conditions are set
by the regulatory authority granting the license to market the
therapy.

Clinical Outcome Assessment
Based on the Food and Drug Administration (FDA) Clinical
Outcome Assessments measure a patient’s symptoms, overall
mental state, or the effects of a disease or condition on how the
patient functions. COAs may be used to determine whether or
not a drug has been demonstrated to provide treatment benefit.
Treatment benefit may also be defined in terms of a safety benefit
compared to other treatments. A conclusion of treatment benefit
is described in labeling in terms of the concept of interest, the
thing measured by the COA1 .

Qualification Criteria
Minimum educational, professional and experiential
considerations required for COA administration or training.

Clinical Evaluator Drift
Refers to the decreased consistency in test administration
over time.

Expert Learner
Individual who understands COA construct, critically
analyzes psychometric properties; develops and validates
COA when needed.

Training
An educational process to determine precise, accurate and
reliable administration and scoring of COAs.

Inter-Rater Reliability
The concordance of agreement between different CEs and/or MP.
It is used to assess the degree to which different evaluators agree
in their assessment decisions.

AUTHOR CONTRIBUTIONS

Intra-Rater Reliability

TD, KJK, MKJ, LN, LNA, KE, EM, KR, LPL, AM, JF, WK, CRS,
and ME contributed to the conception or design of the work or
the acquisition, analysis or interpretation of data for the work,
drafted the work or revised it critically for important intellectual
content, provided the approval for publication of the content, and
agreed to be accountable for all aspects of the work in ensuring
that questions related to the accuracy or integrity of any part of
the work are appropriately investigated and resolved. All authors
contributed to the article and approved the submitted version.

The concordance of agreement of a given CE and/or MP. It is the
degree of agreement among repeated administrations of a clinical
evaluation performed by a single evaluator.

Clinical Outcome Assessment Expert
Trainer
Individual who has expertise in COA development and training.
Exhibits expert-level skill and knowledge; Conveys and teaches
COA to learner(s); adapts teaching style; identifies and conducts
remediation/retraining.

FUNDING

Novice Learner
Individual with foundation of GCP, GDP, clinical research
practice, internal validity risks, best management practices,
roles and responsibilities, basic outcome administration, and
scoring training.

Funding for initial meeting was provided by Federation to
Eradicate Duchenne (FED).
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Post Marketing Surveillance
Post marketing surveillance refers to the collection of subject
data after the approval and marketing of a pharmacological
therapy. Continued collection of safety data that may include
unexpected side effects and continued efficacy of treatment takes
place during this period. This data is usually collected at clinical
sites treating patients with the newly licensed or conditionally
licensed therapy. Accelerated approval mechanisms are now
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